IP Library Granted Patent US 12,194,021
Granted Patent B2
US 12,194,021 · App. 17/728,041 · Granted Jan 14, 2025

Modified herbal compositions for neuromodulation

Inventor: Jing Liang (Los Angeles, CA)
Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
A61K31/353A61K31/198A61K31/4045A61K31/585A61K36/35A61K36/534A61K36/575A61K36/725A61K36/752A61K36/81A61K36/84A61P25/00A61P25/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,021
App. No.
17/728,041
Granted
Jan 14, 2025
Kind
B2
Abstract

Herbal compositions comprising dihydromyricetin (DHM) and methods of use. The herbal compositions include DHM in combination with other ingredients to form compositions that can significantly improve the quality and duration of sleep, reduce the time for onset of improved sleep quality and duration, and treat or alleviate the symptoms of sleep-related disorders and neurological conditions. The composition is a therapeutic alternative to drugs to alleviate sleep disorders and related symptoms and ailments.

Claims (14)

1. A composition comprising dihydromyricetin (DHM) or a salt or complex thereof, magnolia vine extract, jujube kernels extract, Panax notoginseng extract, Hovenia extract, rattan tea extract, vitamin B1, vitamin B3, vitamin B6, vitamin B9, and vitamin B12; wherein a source of the DHM is at least one of the Panax notoginseng extract, the Hovenia extract, and the rattan tea extract; wherein the composition comprises about 5 wt. % DHM to about 40 wt. % DHM; and wherein the composition has a total weight of about 500 mg to about 2000 mg.

2. The composition of claim 1 wherein the DHM is a salt or complex that comprises an alkyl amine or an amino acid.

3. The composition of claim 1 wherein the composition further comprises melatonin, wherein the melatonin is optionally an extended time-release formulation of melatonin.

4. The composition of claim 3 wherein a weight ratio of DHM to melatonin is about 100:1, wherein the melatonin is an extended time-release formulation of melatonin; or

a weight ratio of DHM to melatonin is about 150:1, wherein the melatonin is not an extended time-release formulation of melatonin.

5. The composition of claim 3 wherein a serving of the composition comprises 3 mg±15% melatonin in an extended time-release formulation, 2 mg±15% melatonin that is not in an extended time-release formulation, or a combination thereof.

6. The composition of claim 1 wherein the DHM is stabilized against chemical degradation and its aqueous solubility is enhanced, as compared to unformulated DHM.

7. A method of treating a subject in need of neuromodulation comprising administering to the subject an effective amount of the composition according to claim 1 to provide the neuromodulation, wherein the neuromodulation aids insomnia, sleep, anxiety, or a combination of two or more thereof.

8. The method of claim 7 wherein the neuromodulation aids sleep compared to an untreated control group.

9. The method of claim 8 wherein the neuromodulation shortens the onset of sleep as compared to an untreated control group or to a group treated with only melatonin.

10. The method of claim 7 wherein the neuromodulation aids anxiety compared to an untreated control group.

11. The method of claim 7 wherein the effective amount administered is an oral dose of about 0.5 grams to about 3 grams of the composition.

12. The method of claim 7 wherein a serving of the composition has 300 mg±15% DHM, 200 mg±15% ashwagandha extract, 150 mg±15% valerian extract, 100 mg±15% magnolia extract, 100 mg±15% jujube extract, 100 mg±15% lemon balm, 200 mg±15% L-theanine, optionally 3 mg±15% melatonin in an extended time-release formulation, and optionally 2 mg±15% melatonin that is not in an extended time-release formulation.

13. The method of claim 7 wherein the effective amount is a serving of the composition administered as 1-6 individual capsules or tablets.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 31, 2024
From: UNIVERSITY OF SOUTHERN CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 068217/0267 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2022
From: LIANG, JING
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 060142/0240 →
Continuity (2)
Provisional Application 63192391 · May 24, 2021
Related Publication 20220387379A1 · Dec 8, 2022
References Cited (35)
US 6814987B2 · Stogniew et al. · 2004 [cited by applicant]
US 7935714B2 · Chan et al. · 2011 [cited by applicant]
US 10517322B1 · Lee · 2019 [cited by examiner]
US 11351150B2 · Rinaldi et al. · 2022 [cited by applicant]
US 20060198872A1 · Ikonte et al. · 2006 [cited by applicant]
US 20080039526A1 · Ozeki et al. · 2008 [cited by applicant]
US 20100120887A1 · Terman et al. · 2010 [cited by applicant]
US 20110189161A1 · Blum et al. · 2011 [cited by applicant]
US 20140141082A1 · Gao · 2014 [cited by applicant]
US 20150071993A1 · Patel et al. · 2015 [cited by applicant]
US 20150284667A1 · Edman et al. · 2015 [cited by applicant]
US 20170216176A1 · Chen · 2017 [cited by applicant]
US 20190231711A1 · Weimann · 2019 [cited by applicant]
US 20200138783A1 · Rinaldi · 2020 [cited by examiner]
US 20210113646A1 · Antony · 2021 [cited by examiner]
US 20220257561A1 · Tejani · 2022 [cited by examiner]
AU 2018292531A1 · 2020 [cited by applicant]
CN 108096445A · 2018 [cited by applicant]
CN 109965026A · 2019 [cited by applicant]
CN 110810693A · 2020 [cited by examiner]
EP 1182257B1 · 2005 [cited by applicant]
WO 2019005962A1 · 2019 [cited by applicant]
WO 2020247961A1 · 2020 [cited by applicant]
Rempel, V., et al., Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55, ACS Med. Chem. Lett. Apr. 1, 2013, 41-45 (Year: 2013). [cited by examiner]
Machine translation of CN 110810693 A. [cited by examiner]
Carneiro et al., “Vine Tea ( [cited by applicant]
Carneiro et al., Erratum to “Vine Tea ( [cited by applicant]
Hu et al., “New Method for Extracting and Purifying Dihydromyricetin from Ampelopsis grossedentata,” ACS Omega, 5 (23):13955-13962, Jun. 2020. [cited by applicant]
International Preliminary Report on Patentability of the International Bureau of WIPO in PCT/US2020/036714, dated Dec. 7, 2021; 7pgs. [cited by applicant]
Liu et al., “Dihydromyricetin: A Review on Identification and Quantification Methods, Biological Activities, Chemical Stability, Metabolism and Approaches To Enhance Its Bioavailability,” Trends Food Sci Technol., 91:58… [cited by applicant]
White et al., “Chapter 14 Natural Withanolides in the Treatment of Chronic Diseases,” Adv Exp Med Biol., 928:329-373, Sep. 2016. [cited by applicant]
International Search Report and Written Opinion of the ISA/US dated Aug. 16, 2022 in International Application No. PCT/US2022/030545; 10pgs. [cited by applicant]
Buerger et al., “CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects”, Neurology Aug. 2002; 59:627-629. [cited by applicant]
Milà-Alomà et al., “Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease” Nature Medicine, Sep. 2022, vol. 28, pp. 1797-1801. [cited by applicant]
Suárez-Calvet et al., “Novel tau biomarkers phosphorylated at T181, T217, or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in AB pathology are detected”, EMBO Molecula… [cited by applicant]